Polycarb Disease Interactions
There are 5 disease interactions with Polycarb (polycarbophil).
Bulk producing laxatives (applies to Polycarb) intestinal obstruction
Major Potential Hazard, High plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of bulk producing laxatives is contraindicated in patients with intestinal obstruction or fecal impaction. Bulk producing laxatives can exacerbate these conditions.
References
- "Product Information. FiberCon (polycarbophil)." Lederle Laboratories PROD (2001):
- "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals PROD (2001):
- "Product Information. Unifiber (cellulose)." Niche Pharmaceuticals Inc PROD (2001):
Laxatives (applies to Polycarb) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
- "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc PROD (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Laxatives (applies to Polycarb) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
References
- "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc PROD (2001):
- "Product Information. Fleet Bisacodyl (bisacodyl)." Fleet PROD
- "Product Information. Kondremul Plain (mineral oil)." Bristol-Myers Squibb PROD
- "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet PROD (2001):
- "Product Information. Citrucel (methylcellulose)." SmithKline Beecham PROD (2001):
- "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc PROD (2001):
- "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
- "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
Bulk producing laxatives (applies to Polycarb) renal dysfunction
Moderate Potential Hazard, High plausibility.
Bulk producing laxatives require the consumption of at least 8 ounces of fluid per each dose. Patients with fluid restriction conditions such as renal dysfunction may benefit more from emollient or stimulant laxatives.
References
- "Product Information. FiberCon (polycarbophil)." Lederle Laboratories PROD (2001):
- "Product Information. Metamucil (psyllium)." Procter and Gamble Pharmaceuticals PROD (2001):
Polycarbophil (applies to Polycarb) hypercalcemia
Moderate Potential Hazard, High plausibility.
The use of polycarbophil may cause hypercalcemia. Polycarbophil is supplied as the calcium salt and contains approximately 150 mg (7.6 mEq) of calcium per tablet. Polycarbophil calcium releases calcium ions in the GI tract.
References
- "Product Information. FiberCon (polycarbophil)." Lederle Laboratories PROD (2001):
Polycarb drug interactions
There are 28 drug interactions with Polycarb (polycarbophil).
Polycarb alcohol/food interactions
There is 1 alcohol/food interaction with Polycarb (polycarbophil).
More about Polycarb (polycarbophil)
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.